A new generation of vaccines in the age of immunotherapy
Cargando...
Fecha
2021
Autores
Título de la revista
Publicado en
Current Oncology Reports, 1523-3790, Vol 23, Num 12, 2021
Publicado por
Springer
URL de la fuente
Enlace a contenidos multimedia
ISSN de la revista
Título del volumen
Resumen
Purpose of review
Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field.
Recent findings
In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome.
Summary
Cancer vaccination has experienced tremendous progress in the last decade, with myriad promising developments. Future efforts should focus on optimization of target identification, streamlining of most appropriate vaccination strategies, and adjuvant development, as well as predictive biomarker identification. Cautious optimism is warranted in the face of early successes seen in recent clinical trials for oncolytic vaccines. If an approach were to prove successful, it could revolutionize cancer therapy the way ICIs did in the previous decade.
Descripción
Abstract
Purpose of review
Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field.
Recent findings
In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome.
Summary
Cancer vaccination has experienced tremendous progress in the last decade, with myriad promising developments. Future efforts should focus on optimization of target identification, streamlining of most appropriate vaccination strategies, and adjuvant development, as well as predictive biomarker identification. Cautious optimism is warranted in the face of early successes seen in recent clinical trials for oncolytic vaccines. If an approach were to prove successful, it could revolutionize cancer therapy the way ICIs did in the previous decade.
Palabras clave
Keywords
Immunotherapy, Lung cancer, NSCLC, Vaccines